Skip to main content
    PeptideAuthority
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Share:X PostLinkedIn
    Fat Loss & Metabolic•Updated 2026-02-01•5 min read

    What Is Amylin? Benefits, Research & Safety

    A pancreatic hormone co-secreted with insulin that regulates glucose and appetite, the basis for the diabetes drug pramlintide.

    Share:X PostLinkedIn
    Also known as:
    Islet Amyloid Polypeptide
    IAPP
    Pramlintide base
    BModerate human evidenceUK: Unlicensed (UK)WADA: Sport status unclear

    UK summary: Endogenous pancreatic peptide. Pramlintide (Symlin) is licensed in the US for type 1 / type 2 diabetes; not currently licensed in the UK. Cagrilintide (an analogue) is in late-stage clinical development with Novo Nordisk for obesity.

    Quick Facts

    Category
    Fat Loss & Metabolic
    Half-Life
    Approximately 50 minutes (pramlintide)
    UK Status
    Pramlintide not widely available; not commonly used in UK practice.
    EU Status
    Pramlintide not approved in EU.

    Overview

    Amylin (also known as islet amyloid polypeptide or IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It works alongside insulin to regulate blood glucose, with complementary but distinct mechanisms. While insulin promotes glucose uptake and storage, amylin primarily regulates the rate of glucose entry into the bloodstream. It slows gastric emptying, suppresses glucagon secretion, and reduces appetite—all actions that help prevent postprandial glucose spikes. In type 1 diabetes, amylin is absent (along with insulin); in type 2 diabetes, amylin secretion is impaired. This has led to development of amylin analogues as diabetes treatments. Pramlintide (Symlin) is a synthetic analogue of amylin approved for diabetes treatment. It improves glycemic control and often produces modest weight loss due to appetite-suppressing effects. Amylin's glucoregulatory and appetite effects have also generated interest in obesity treatment, leading to the development of cagrilintide and combination therapies (like cagrisema—cagrilintide plus semaglutide) currently in clinical development.
    Evidence standards summary

    Amylin — evidence and risk at a glance

    Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

    01Evidence snapshot

    BModerate human evidenceOverall grade against our evidence grading methodology.

    Endogenous pancreatic peptide. Pramlintide (Symlin) is licensed in the US for type 1 / type 2 diabetes; not currently licensed in the UK. Cagrilintide (an analogue) is in late-stage clinical development with Novo Nordisk for obesity.

    02Human evidence grade

    BModerate human evidenceStrength of evidence from published human trials.

    03Preclinical evidence grade

    AStrong human evidenceAnimal-model and in-vitro evidence quality.

    04Regulatory status

    • UK: Pramlintide not widely available; not commonly used in UK practice.
    • EU: Pramlintide not approved in EU.
    • Notes: Pramlintide is FDA-approved in the US for diabetes. Not approved in UK/EU. Cagrilintide (long-acting analogue) is in development; cagrisema (cagrilintide + semaglutide) is in Phase 3 for obesity with very promising results.

    05Approved medical uses

    • Pramlintide (SymlinPen) — licensed in the US for type 1 / type 2 diabetes adjunct to insulin (NOT MHRA-licensed in UK).

    06Unapproved / promotional claims

    • Amylin available for UK private prescription.
    • Equivalent to GLP-1s for weight loss.

    07Common internet claims

    • Marketed by some grey-market vendors as cagrilintide / amylin-pathway products.

    08Claim vs evidence

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Available in the UK as a diabetes treatment”ENoHighPramlintide is not licensed in the UK. UK diabetes pathways use other agents.
    “Suppresses appetite as effectively as GLP-1”CYesModerateAmylin analogues show appetite-suppression and post-prandial glycaemia effects; head-to-head trials vs GLP-1 are emerging.

    09Safety uncertainty score

    Moderate

    Safety profile partly characterised; some signals from observational or preclinical data.

    10Known adverse signals

    • Hypoglycaemia (when combined with insulin).
    • GI side effects (nausea).
    • Injection-site reactions.

    11Drug-interaction uncertainty

    Moderate

    Some interaction data published; check with a prescriber for your specific medicines.

    12Anti-doping status

    WADA: Sport status unclearWADA strict-liability framing applies.

    13UK legal position

    UK: Unlicensed (UK)

    Pramlintide not widely available; not commonly used in UK practice.

    Read the full UK legal guide → Are peptides legal in the UK?

    14EU legal position

    Pramlintide not approved in EU.

    15What this page cannot tell you

    • Whether grey-market amylin / cagrilintide products contain the labelled compound.
    • Long-term safety of off-label cosmetic-weight use.

    16Last reviewed

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    17Citation quality score

    BModerate human evidenceQuality of the sources we cite, graded against the evidence grading methodology.

    18Research gaps

    • Cagrilintide Phase 3 (CagriSema) results awaited.
    • Long-term amylin pathway safety beyond licensed pramlintide indication limited.

    19Safer alternatives / established care pathways

    • Licensed Wegovy / Mounjaro for clinically appropriate weight management.
    • NHS diabetes pathway for diabetes management.

    20Doctor discussion prompts

    Questions to ask a qualified clinician

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Are amylin analogues a UK-licensed option for diabetes or weight management?
    • What licensed alternatives should I consider first?

    Discovery & History

    Amylin was discovered in 1987 by Garth Cooper and colleagues, who isolated it from amyloid deposits in the pancreatic islets of patients with type 2 diabetes. The peptide was named for its tendency to form amyloid fibrils. Initial research focused on the potential role of amylin aggregation in beta cell dysfunction and type 2 diabetes pathophysiology. The amyloid deposits seen in diabetic islets were composed primarily of aggregated IAPP. Subsequent research revealed amylin's physiological functions as a hormone. Studies showed it complemented insulin by slowing gastric emptying, suppressing glucagon, and reducing food intake—all beneficial for glucose control. Recognition that amylin was deficient in diabetes (absolute in type 1, relative in type 2) suggested therapeutic potential for amylin replacement. However, human amylin's tendency to aggregate complicated drug development. Amylin Pharmaceuticals developed pramlintide, a modified amylin with three amino acid substitutions that prevent aggregation. Pramlintide (Symlin) received FDA approval in 2005 for use alongside insulin in type 1 and type 2 diabetes. Current development focuses on longer-acting amylin analogues and combination therapies. Cagrilintide (a long-acting amylin analogue) combined with semaglutide (GLP-1 agonist) is in advanced development for obesity and shows particularly promising weight loss results.

    Mechanism of Action

    Amylin acts through specific receptors to complement insulin's actions: **Amylin Receptors** Amylin binds to calcitonin receptor complexed with RAMPs: - Calcitonin receptor + RAMP1, 2, or 3 creates amylin receptors - Widely distributed in brain, gut, and other tissues - Activates cAMP signaling **Gastric Emptying** Slowing stomach emptying: - Delays glucose entry into bloodstream - Reduces postprandial glucose peaks - Contributes to satiety **Glucagon Suppression** Inhibits inappropriate glucagon release: - Glucagon normally raises blood glucose - Amylin suppresses glucagon after meals - Helps prevent postprandial hyperglycemia **Appetite and Food Intake** Central effects on appetite: - Activates satiety centers in brainstem - Reduces meal size - May affect food reward **Complementary to Insulin** Works alongside insulin but differently: - Insulin promotes glucose uptake - Amylin regulates glucose rate of entry - Together they optimise glucose control

    Researched Benefits

    Based on preclinical and clinical research findings:

    • 1
      Improved postprandial glucose control
    • 2
      Reduced HbA1c in diabetes (pramlintide)
    • 3
      Weight loss or prevention of weight gain
    • 4
      Reduced glucagon spikes after meals
    • 5
      Satiety enhancement and reduced food intake
    • 6
      Potential for combination obesity therapy (with GLP-1 agonists)

    Claim vs Evidence

    How popular claims about Amylin stack up against the current research, graded using our public evidence grading methodology.

    ClaimEvidenceHuman evidence?Regulatory concernSafer wording
    “Available in the UK as a diabetes treatment”ENoHighPramlintide is not licensed in the UK. UK diabetes pathways use other agents.
    “Suppresses appetite as effectively as GLP-1”CYesModerateAmylin analogues show appetite-suppression and post-prandial glycaemia effects; head-to-head trials vs GLP-1 are emerging.

    Theoretical Dosing & Protocols

    ⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
    Theoretical DosagePramlintide: 15-120 mcg before meals (FDA approved doses)
    FrequencyBefore major meals (3 times daily)
    DurationOngoing with diabetes management
    NotesPramlintide is approved for use with insulin in type 1 and type 2 diabetes. Must be used alongside appropriate insulin dose reduction to avoid hypoglycemia. Not used as monotherapy. Medical supervision required.

    Administration Routes

    Routes studied in research settings (educational only):

    • Subcutaneous injection (pramlintide)
    • Longer-acting analogues in development
    Half-LifeStability
    Approximately 50 minutes (pramlintide)Pramlintide stable in solution per manufacturer specifications

    Safety Profile & Known Risks

    Commonly Reported Side Effects

    • Nausea (common initially, usually improves)
    • Headache
    • Anorexia/reduced appetite
    • Vomiting
    • Injection site reactions

    Rare Risks & Concerns

    • Severe hypoglycemia (especially with inadequate insulin adjustment)
    • Gastroparesis (avoid in patients with this condition)

    Contraindications

    • Gastroparesis
    • Hypoglycemia unawareness
    • Use requires appropriate insulin dose reduction
    • Not for use in place of insulin

    UK & EU Regulatory Context

    🇬🇧 United Kingdom

    Pramlintide not widely available; not commonly used in UK practice.

    🇪🇺 European Union

    Pramlintide not approved in EU.

    Pramlintide is FDA-approved in the US for diabetes. Not approved in UK/EU. Cagrilintide (long-acting analogue) is in development; cagrisema (cagrilintide + semaglutide) is in Phase 3 for obesity with very promising results.

    Clinical Studies Summary

    Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.

    Novel ABTs, such as HiD amycretin, CagriSema and eloralintide, may induce substantial short- to medium-term weight loss but may also increase GI AEs; given sparse, low-certainty data, these findings are preliminary and require confirmation in larger trials. The review protocol summary can be accessed at the PROSPERO website (

    Endocrinol Diabetes Metab. 2026View on PubMed

    Neuropathological links between T2DM and LOAD: systematic review and meta-analysis.

    Overall accumulated results highlight the insulin signaling system, vascular markers, inflammation and inflammasome pathways, amylin interactions, and glycosylation mechanisms. The protocol was registered with PROSPERO (ID: CRD42023440535).

    Physiol Rev. 2025View on PubMed

    Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

    Our findings show cardiovascular safety across all GLP-1 receptor agonist cardiovascular outcome trials and suggest that drugs in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality risk, albeit to varying degrees for individual drugs, without significant safety concerns.

    Lancet Diabetes Endocrinol. 2018View on PubMed

    Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

    In people with overweight or obesity, amycretin appeared safe and tolerable. Results from this first-in-human, phase 1 study support further investigation of the weight loss properties of amycretin.

    Lancet. 2025View on PubMed

    Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

    Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.

    Mol Metab. 2025View on PubMed

    Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

    In people with overweight or obesity, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists. Although a high frequency of gastrointestinal events was reported, rates were similar to those seen in early-phase studies of these molecules. These results support further investigation into the weight loss properties of amycretin.

    Lancet. 2025View on PubMed

    Registered Trials & Regulatory Status

    Registered trials
    16
    Currently recruiting
    5
    Furthest phase
    Phase 4
    Approved product
    No

    6 of 6 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.

    Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

    PHASE1

    Status: Recruiting · 100 participants · Novo Nordisk A/S

    Conditions: Obesity

    No results postedNCT07527195

    Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

    NA

    Status: Recruiting · 18 participants · University Hospital, Gentofte, Copenhagen

    Conditions: Obesity & Overweight

    No results postedNCT07506369

    A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

    PHASE1

    Status: Recruiting · 100 participants · Novo Nordisk A/S

    Conditions: Overweight, Obese

    No results postedNCT07411560

    Hypersensitivity to Amylin in Post-Traumatic Headache

    NA

    Status: Not Yet Recruiting · 21 participants · Danish Headache Center

    Conditions: Headache Disorders, Secondary, Brain Diseases, Headache Disorders

    No results postedNCT07340775

    Amylin-Induced Migraine Attacks Without Aura

    NA

    Status: Not Yet Recruiting · 21 participants · Danish Headache Center

    Conditions: Headache Disorders, Primary, Headache Disorders, Brain Diseases

    No results postedNCT07340788

    The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    PHASE1

    Status: Recruiting · 144 participants · Novo Nordisk A/S

    Conditions: Obesity

    No results postedNCT07010432

    "Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"

    N/A

    Status: Not Yet Recruiting · 216 participants · Fundación Marques de Valdecilla

    Conditions: High Frequency Episodic Migraine and Chronic Migraine

    No results postedNCT06692088

    The Role of Amylin in Bone Metabolism

    NA

    Status: Unknown · 20 participants · Filip Krag Knop

    Conditions: Bone Diseases, Metabolic, Type 1 Diabetes

    No results postedNCT06186063

    Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients

    NA

    Status: Completed · 36 participants · Danish Headache Center

    Conditions: Migraine Without Aura

    No results postedNCT03598075

    A Causative Role for Amylin in Diabetic Peripheral Neuropathy

    N/A

    Status: Recruiting · 40 participants · Zabeen Mahuwala, MD

    Conditions: Type2 Diabetes, Peripheral Neuropathy

    No results postedNCT03481283

    Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patients

    N/A

    Status: Completed · 80 participants · Recep Tayyip Erdogan University Training and Research Hospital

    Conditions: Polycystic Ovary Syndrome

    No results postedNCT03587415

    Myocardial Protection of Exenatide in AMI

    PHASE4

    Status: Completed · 127 participants · Kyunghee University Medical Center

    Conditions: Myocardial Infarction

    No results postedNCT01580514

    Adverse event reports (FDA FAERS)

    Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.

    Source: ClinicalTrials.gov and openFDA. Updated automatically.

    Looking for Amylin?

    Source research-grade Amylin from a trusted UK supplier — third-party tested with certificate of analysis.

    View at Supplier

    Frequently Asked Questions

    Questions to ask a qualified clinician about Amylin

    These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

    • Are amylin analogues a UK-licensed option for diabetes or weight management?
    • What licensed alternatives should I consider first?

    UK regulatory & safety context

    Are peptides legal in the UK?

    UK legal reference

    Related Peptides

    Semaglutide

    A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.

    Learn more

    Liraglutide

    An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.

    Learn more

    GLP-1

    A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.

    Learn more

    Ghrelin

    The 'hunger hormone' that stimulates appetite and growth hormone release, with important roles in metabolism and energy balance.

    Learn more

    Explore More Peptides

    Browse our comprehensive database of research-backed peptide profiles.